This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bicarbonate in paediatric ALS

Authoring team

Sodium bicarbonate is often used in the resuscitation of children, with the aim of reducing the acidosis presumed to occur during an arrest.

  • cardiac arrest results in combined respiratory and metabolic acidosis, caused by cessation of pulmonary gas exchange, and the development of anaerobic cellular metabolism respectively
    • best treatment for acidaemia in cardiac arrest is a combination of chest compression and ventilation. Furthermore, giving bicarbonate causes generation of carbon dioxide which diffuses rapidly into the cells. This has the following effects:
      • exacerbates intracellular acidosis
      • produces a negative inotropic effect on ischaemic myocardium
      • presents a large, osmotically active, sodium load to an already compromised circulation and brain
      • produces a shift to the left in the oxygen dissociation curve further inhibiting release of oxygen to the tissues
    • routine use of sodium bicarbonate in cardiac arrest is not recommended.
      • may be considered in prolonged arrest, and it has a specific role in hyperkalaemia and the arrhythmias associated with tricyclic antidepressant overdose. The dose is 1-2 ml per kg of the 8.4% solution given by the IV or IO routes

Reference:

  1. Resuscitation Council (UK). Advanced Paediatric Life Support. Guidelines 2005.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.